Azithromycin Mass Treatment for Trachoma Control: Risk Factors for Non-Participation of Children in Two Treatment Rounds

被引:18
|
作者
Ssemanda, Elizabeth N. [1 ]
Levens, Joshua [1 ]
Mkocha, Harran [2 ]
Munoz, Beatriz [1 ]
West, Sheila K. [1 ]
机构
[1] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA
[2] Kongwa Trachoma Project, Kongwa, Tanzania
来源
PLOS NEGLECTED TROPICAL DISEASES | 2012年 / 6卷 / 03期
关键词
D O I
10.1371/journal.pntd.0001576
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Backgroud: Persistent non-participation of children in mass drug administration (MDAs) for trachoma may reduce program impact. Risk factors that identify families where participation is a problem or program characteristics that foster non-participation are poorly understood. We examined risk factors for households with at least one child who did not participate in two MDAs compared to households where all children participated in both MDAs. Methods/Principal Findings: We conducted a case control study in 28 Tanzanian communities. Cases included all 152 households with at least one child who did not participate in the 2008 and 2009 MDAs with azithromycin. Controls consisted of a random sample of 460 households where all children participated in both MDAs. A questionnaire was asked of all families. Random-intercept logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), control for clustering, and adjust for community size. In total, 140 case households and 452 control households were included in the analyses. Compared to controls, guardians in case households had higher odds of reporting excellent health (OR 4.12 (CI 95% 1.57-10.86)), reporting a burden due to family health (OR 3.15 (95% CI 1.35-7.35)), reduced ability to rely on others for assistance (OR 1.66 (95% CI 1.01-2.75)), being in a two (versus five) days distribution program (OR 3.31 (95% CI 1.68-6.50)) and living in a community with <2 community treatment assistants (CTAs)/1000 residents (OR 2.07 (95% CI 1.04-4.12). Furthermore, case households were more likely to have more children, younger guardians, unfamiliarity with CTAs, and CTAs with more travel time to their assigned households (p-values<0.05). Conclusions/Significance: Compared to full participation households, households with persistent non-participation had a higher burden of familial responsibility and seemed less connected in the community. Additional distribution days and lessening CTAs' travel time to their furthest assigned households may prevent non-participation.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] IMPACT OF MASS AZITHROMYCIN TREATMENT ON THE PREVALENCE OF ACTIVE TRACHOMA AND OCULAR CHLAMYDIA TRACHOMATIS IN THE GAMBIA
    Harding-Esch, Emma
    Holland, Martin J.
    Sillah, Ansumana
    Molina, Sandra
    Aguirre-Andreasen, Aura
    Snell, Paul
    Edwards, Tansy
    Bailey, Robin L.
    Mabey, David C.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 360 - 360
  • [32] Concordance of ompA types in children re-infected with ocular Chlamydia trachomatis following mass azithromycin treatment for trachoma
    Mosenia, Arman
    Chin, Stephanie A.
    Alemayehu, Wondu
    Melese, Muluken
    Lakew, Takele
    Zhou, Zhaoxia
    Doan, Thuy
    Cevallos, Vicky
    Lietman, Thomas M.
    Keenan, Jeremy D.
    PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (03):
  • [33] Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia
    Ebert, Caleb D.
    Astale, Tigist
    Sata, Eshetu
    Zerihun, Mulat
    Nute, Andrew W.
    Stewart, Aisha E. P.
    Gessese, Demelash
    Ayenew, Gedefaw
    Ayele, Zebene
    Melak, Berhanu
    Chanyalew, Melsew
    Gashaw, Bizuayehu
    Tadesse, Zerihun
    Callahan, E. Kelly
    Jenness, Samuel M.
    Nash, Scott D.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2019, 24 (04) : 493 - 501
  • [34] Effect of Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian Children A Randomized Trial
    Porco, Travis C.
    Gebre, Teshome
    Ayele, Berhan
    House, Jenafir
    Keenan, Jeremy
    Zhou, Zhaoxia
    Hong, Kevin Cyrus
    Stoller, Nicole
    Ray, Kathryn J.
    Emerson, Paul
    Gaynor, Bruce D.
    Lietman, Thomas M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (09): : 962 - 968
  • [35] Changes in trachoma indicators in Kiribati with two rounds of azithromycin mass drug administration, measured in serial population-based surveys
    Goodhew, E. Brook
    Taoaba, Raebwebwe
    Harding-Esch, Emma M.
    Gwyn, Sarah E.
    Bakhtiari, Ana
    Butcher, Robert
    Cama, Anasaini
    Guagliardo, Sarah Anne J.
    Jimenez, Cristina
    Mpyet, Caleb D.
    Tun, Kab
    Wickens, Karana
    Solomon, Anthony W.
    Martin, Diana L.
    Tekeraoi, Rabebe
    PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (07):
  • [36] Risk factors for non-participation in a universal developmental surveillance program in a population in Australia
    Ayer, Chandra
    Eapen, Valsamma
    Overs, Bronwyn
    Descallar, Joseph
    Jalaludin, Bin
    Eastwood, John Graeme
    Dissanayake, Cheryl
    Williams, Katrina
    Murphy, Elisabeth
    Woolfenden, Susan
    AUSTRALIAN HEALTH REVIEW, 2020, 44 (04) : 512 - 520
  • [37] Chlamydia on children and flies after mass antibiotic treatment for trachoma
    Lee, Scott
    Alemayehu, Wondu
    Melese, Muluken
    Lakew, Takele
    Lee, David
    Yi, Elizabeth
    Cevallos, Vicky
    Donnellan, Cathy
    Zhou, Zhaoxia
    Chidambaram, Jaya D.
    Gaynor, Bruce D.
    Whitcher, John P.
    Lietman, Thomas M.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 76 (01): : 129 - 131
  • [38] Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal
    Fry, AM
    Jha, HC
    Lietman, TM
    Chaudhary, JSP
    Bhatta, RC
    Elliott, J
    Hyde, T
    Schuchat, A
    Gaynor, B
    Dowell, SF
    CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) : 395 - 402
  • [39] Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness
    Huguet, P.
    Bella, L.
    Einterz, E. M.
    Goldschmidt, P.
    Bensaid, P.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (02) : 157 - 160
  • [40] Mass antibiotic treatment and community protection in trachoma control programs
    Chidambaram, JD
    Melese, M
    Alemayehu, W
    Yi, E
    Prabriputaloong, T
    Lee, DC
    Cevallos, V
    Zhou, ZX
    Whitcher, JP
    Gaynor, BD
    Lietman, TM
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (09) : E95 - E97